Patents by Inventor Valerie Morisset

Valerie Morisset has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING OF CV-10155 IN THE EVENING OR PRIOR TO SLEEP TO TREAT GABAA DISORDERS
    Publication number: 20220296614
    Abstract: The invention provides methods for treating a GABAA disorders by providing a composition containing CV-10155 to a subject in the evening or prior to a period of sleep by the subject.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 22, 2022
    Inventors: Joanne Palmer-Phillips, Elizabeth Mitchell, Valerie Morisset, Amy Chappell
  • FOOD-INDEPENDENT DOSING OF CV-10155 TO TREAT GABAA DISORDERS
    Publication number: 20220296613
    Abstract: The invention provides methods of treating a GABAA disorder in a subject by providing an oral dose of a composition that contains CV-10155 during a dosing window in which the subject does not consume food.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 22, 2022
    Inventors: Joanne Palmer-Phillips, Elizabeth Mitchell, Valerie Morisset, Amy Chappell
  • DIAGNOSTIC METHOD
    Publication number: 20220098664
    Abstract: The invention relates to a method of diagnosing a paroxysmal pain disorder, such as trigeminal neuralgia, in a human subject and also provides a method of identifying patients most likely to respond to therapy and to kits for use in said methods.
    Type: Application
    Filed: May 17, 2021
    Publication date: March 31, 2022
    Inventor: Valerie Morisset
  • PAROXYSMAL EXTREME PAIN DISORDER TREATMENT
    Publication number: 20200147041
    Abstract: The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: October 17, 2019
    Publication date: May 14, 2020
    Inventor: Valerie Morisset
  • NOVEL ERYTHROMELALGIA TREATMENT
    Publication number: 20190388391
    Abstract: The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: January 22, 2019
    Publication date: December 26, 2019
    Inventor: Valerie Morisset
  • Paroxysmal extreme pain disorder treatment
    Patent number: 10493059
    Abstract: The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: December 3, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventor: Valerie Morisset
  • NOVEL DOSAGE REGIMEN
    Publication number: 20190255019
    Abstract: The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 22, 2019
    Inventors: Valerie Morisset, Himanshu Naik, Joi Dunbar, Mark Versavel
  • Erythromelalgia treatment
    Patent number: 10231950
    Abstract: The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: March 19, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventor: Valerie Morisset
  • Novel Erythromelalgia Treatment
    Publication number: 20170304264
    Abstract: The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Inventor: Valerie Morisset
  • Paroxysmal Extreme Pain Disorder Treatment
    Publication number: 20170304265
    Abstract: The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Inventor: Valerie Morisset
  • Novel Small Fibre Neuropathy Treatment
    Publication number: 20170290802
    Abstract: The present invention is directed to the treatment of small fibre neuropathy comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 12, 2017
    Inventor: Valerie Morisset
  • DIAGNOSTIC METHOD
    Publication number: 20170096708
    Abstract: The invention relates to a method of diagnosing a paroxysmal pain disorder, such as trigeminal neuralgia, in a human subject and also provides a method of identifying patients most likely to respond to therapy and to kits for use in said methods.
    Type: Application
    Filed: June 3, 2015
    Publication date: April 6, 2017
    Inventor: Valerie Morisset